Published in Ann Hum Genet on March 05, 2008
Efficient TALEN-mediated gene knockout in livestock. Proc Natl Acad Sci U S A (2012) 4.99
Exome sequencing identifies rare LDLR and APOA5 alleles conferring risk for myocardial infarction. Nature (2014) 3.29
Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study. Eur Heart J (2008) 2.50
Large-scale gene-centric meta-analysis across 32 studies identifies multiple lipid loci. Am J Hum Genet (2012) 1.96
Low prevalence of mutations in known loci for autosomal dominant hypercholesterolemia in a multiethnic patient cohort. Circ Cardiovasc Genet (2012) 1.51
Exome sequencing in suspected monogenic dyslipidemias. Circ Cardiovasc Genet (2015) 1.51
Incomplete knowledge of the clinical context as a barrier to interpreting incidental genetic research findings. Am J Bioeth (2013) 1.48
Systematic cell-based phenotyping of missense alleles empowers rare variant association studies: a case for LDLR and myocardial infarction. PLoS Genet (2015) 1.47
The role of large pedigrees in an era of high-throughput sequencing. Hum Genet (2012) 1.37
Mechanistic implications for LDL receptor degradation from the PCSK9/LDLR structure at neutral pH. EMBO Rep (2011) 1.31
GIGI: an approach to effective imputation of dense genotypes on large pedigrees. Am J Hum Genet (2013) 1.15
Elevated PCSK9 levels in untreated patients with heterozygous or homozygous familial hypercholesterolemia and the response to high-dose statin therapy. J Am Heart Assoc (2013) 1.08
Hypercholesterolemia and microvascular dysfunction: interventional strategies. J Inflamm (Lond) (2010) 1.06
Familial hypercholesterolemia: the lipids or the genes? Nutr Metab (Lond) (2011) 1.04
Founder mutations in the Netherlands: geographical distribution of the most prevalent mutations in the low-density lipoprotein receptor and apolipoprotein B genes. Neth Heart J (2011) 1.00
Mechanism of LDL binding and release probed by structure-based mutagenesis of the LDL receptor. J Lipid Res (2009) 0.97
Analysis of the frequency and spectrum of mutations recognised to cause familial hypercholesterolaemia in routine clinical practice in a UK specialist hospital lipid clinic. Atherosclerosis (2013) 0.96
Use of a genetic isolate to identify rare disease variants: C7 on 5p associated with MS. Hum Mol Genet (2009) 0.96
Mechanisms and genetic determinants regulating sterol absorption, circulating LDL levels, and sterol elimination: implications for classification and disease risk. J Lipid Res (2011) 0.96
Molecular spectrum of autosomal dominant hypercholesterolemia in France. Hum Mutat (2010) 0.95
Molecular genetics of atherosclerosis. Hum Genet (2009) 0.95
The biology of PCSK9 from the endoplasmic reticulum to lysosomes: new and emerging therapeutics to control low-density lipoprotein cholesterol. Drug Des Devel Ther (2013) 0.94
LDLR-Gene therapy for familial hypercholesterolaemia: problems, progress, and perspectives. Int Arch Med (2010) 0.91
Familial hypercholesterolemia: A review. Ann Pediatr Cardiol (2014) 0.91
Reciprocal regulation of endocytosis and metabolism. Cold Spring Harb Perspect Biol (2014) 0.89
Analysis of sequence variations in low-density lipoprotein receptor gene among Malaysian patients with familial hypercholesterolemia. BMC Med Genet (2011) 0.87
An integrated approach to the interpretation of single amino acid polymorphisms within the framework of CATH and Gene3D. BMC Bioinformatics (2009) 0.87
Profile of evolocumab and its potential in the treatment of hyperlipidemia. Drug Des Devel Ther (2015) 0.85
Functional characterization of two low-density lipoprotein receptor gene mutations in two Chinese patients with familial hypercholesterolemia. PLoS One (2014) 0.85
A Mechanistic Systems Pharmacology Model for Prediction of LDL Cholesterol Lowering by PCSK9 Antagonism in Human Dyslipidemic Populations. CPT Pharmacometrics Syst Pharmacol (2014) 0.85
Functional analysis of four LDLR 5'UTR and promoter variants in patients with familial hypercholesterolaemia. Eur J Hum Genet (2014) 0.85
Low-density lipoprotein cholesterol, apolipoprotein B, and risk of coronary heart disease: from familial hyperlipidemia to genomics. Biol Res Nurs (2012) 0.84
Mipomersen and other therapies for the treatment of severe familial hypercholesterolemia. Vasc Health Risk Manag (2012) 0.82
Targeted genetic testing for familial hypercholesterolaemia using next generation sequencing: a population-based study. BMC Med Genet (2014) 0.82
The MYLIP p.N342S polymorphism is associated with response to lipid-lowering therapy in Brazilian patients with familial hypercholesterolemia. Pharmacogenet Genomics (2014) 0.79
Advantages and versatility of fluorescence-based methodology to characterize the functionality of LDLR and class mutation assignment. PLoS One (2014) 0.78
Leveraging human genetics to guide drug target discovery. Trends Cardiovasc Med (2016) 0.78
Genomic characterization of large rearrangements of the LDLR gene in Czech patients with familial hypercholesterolemia. BMC Med Genet (2010) 0.78
Low-density lipoprotein receptor mutations generate synthetic genome-wide associations. Eur J Hum Genet (2012) 0.78
The genetic spectrum of familial hypercholesterolemia in Pakistan. Clin Chim Acta (2013) 0.78
Genetic polymorphisms in LDLR, APOB, PCSK9 and other lipid related genes associated with familial hypercholesterolemia in Malaysia. PLoS One (2013) 0.77
Changes in Lipids and Lipoproteins after Selective LDL Apheresis (7-Year Experience). Cholesterol (2012) 0.77
Mutational analysis of a cohort with clinical diagnosis of familial hypercholesterolemia: considerations for genetic diagnosis improvement. Genet Med (2015) 0.77
Mitotic spindle defects and chromosome mis-segregation induced by LDL/cholesterol-implications for Niemann-Pick C1, Alzheimer's disease, and atherosclerosis. PLoS One (2013) 0.77
Pharmacogenetic aspects in familial hypercholesterolemia with the special focus on FHMarburg (FH p.W556R). Clin Res Cardiol Suppl (2012) 0.76
The genetics and screening of familial hypercholesterolaemia. J Biomed Sci (2016) 0.76
Premature coronary heart disease and autosomal dominant hypercholesterolemia: Increased risk in women with LDLR mutations. J Clin Lipidol (2015) 0.76
The use of targeted exome sequencing in genetic diagnosis of young patients with severe hypercholesterolemia. Sci Rep (2016) 0.75
The distribution and characteristics of LDL receptor mutations in China: A systematic review. Sci Rep (2015) 0.75
Autosomal recessive hypercholesterolaemia in a Morrocan family due to a mutation of the G266C LDL receptor. BMJ Case Rep (2012) 0.75
Identification of a novel nonsense variant c.1332dup, p.(D445*) in the LDLR gene that causes familial hypercholesterolemia. Hum Genome Var (2014) 0.75
Quality assessment of the genetic test for familial hypercholesterolemia in the Netherlands. Cholesterol (2013) 0.75
Novel low density lipoprotein receptor variant linked to early onset acute myocardial infarction in a patient with familial hypercholesterolaemia. JRSM Open (2014) 0.75
The genetic spectrum of familial hypercholesterolemia in south-eastern Poland. Metabolism (2015) 0.75
The UCL low-density lipoprotein receptor gene variant database: pathogenicity update. J Med Genet (2016) 0.75
Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link? Atherosclerosis (2000) 4.88
Errors in the polymerase chain reaction. Nucleic Acids Res (1988) 3.52
Cholesteryl ester transfer protein TaqIB variant, high-density lipoprotein cholesterol levels, cardiovascular risk, and efficacy of pravastatin treatment: individual patient meta-analysis of 13,677 subjects. Circulation (2005) 2.77
Human CRP gene polymorphism influences CRP levels: implications for the prediction and pathogenesis of coronary heart disease. Arterioscler Thromb Vasc Biol (2003) 2.63
Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ten-country panel. J Intern Med (2006) 2.55
Extent of underdiagnosis of familial hypercholesterolaemia in routine practice: prospective registry study. BMJ (2000) 2.40
Electrophoresis for genotyping: microtiter array diagonal gel electrophoresis on horizontal polyacrylamide gels, hydrolink, or agarose. Anal Biochem (1994) 2.38
Progression of coronary atherosclerosis is associated with a common genetic variant of the human stromelysin-1 promoter which results in reduced gene expression. J Biol Chem (1996) 2.36
Interleukin-6 (IL-6) and the prognosis of abdominal aortic aneurysms. Circulation (2001) 2.29
Interleukin-6 gene -174g>c and -572g>c promoter polymorphisms are strong predictors of plasma interleukin-6 levels after coronary artery bypass surgery. Arterioscler Thromb Vasc Biol (2001) 1.96
Increased incidence of neoplasia of the digestive tract in men with persistent activation of the coagulant pathway. J Thromb Haemost (2004) 1.91
Role of genetic variation at the fibrinogen locus in determination of plasma fibrinogen concentrations. Lancet (1987) 1.85
Genetics of inflammation and risk of coronary artery disease: the central role of interleukin-6. Eur Heart J (2000) 1.83
Screening for hypercholesterolaemia versus case finding for familial hypercholesterolaemia: a systematic review and cost-effectiveness analysis. Health Technol Assess (2000) 1.80
Human gene for physical performance. Nature (1998) 1.78
Genetic causes of familial hypercholesterolaemia in patients in the UK: relation to plasma lipid levels and coronary heart disease risk. J Med Genet (2006) 1.76
Relationship between markers of activated coagulation, their correlation with inflammation, and association with coronary heart disease (NPHSII). J Thromb Haemost (2007) 1.67
A common DNA polymorphism of the low-density lipoprotein (LDL) receptor gene and its use in diagnosis. Lancet (1985) 1.64
The isolation of a clone for human alpha 1-antitrypsin and the detection of alpha 1-antitrypsin in mRNA from liver and leukocytes. Biochem Biophys Res Commun (1983) 1.62
A study of DNA polymorphisms around the human apolipoprotein AI gene in hyperlipidaemic and normal individuals. Clin Genet (1985) 1.62
There are approximately 20 actin gene in the human genome. Nucleic Acids Res (1981) 1.58
Risk of fatal stroke in patients with treated familial hypercholesterolemia: a prospective registry study. Stroke (2003) 1.57
Variation in the PPARalpha gene is associated with altered function in vitro and plasma lipid concentrations in Type II diabetic subjects. Diabetologia (2000) 1.54
Isolation and characterisation of a cDNA clone for human apolipoprotein CI and assignment of the gene to chromosome 19. Hum Genet (1985) 1.53
Myotoxicity of local anesthetics and regeneration of the damaged muscle fibers. Anesth Analg (1980) 1.49
Effects of sample handling on the stability of interleukin 6, tumour necrosis factor-alpha and leptin. Cytokine (2000) 1.46
Glu298Asp endothelial nitric oxide synthase gene polymorphism interacts with environmental and dietary factors to influence endothelial function. Circ Res (2002) 1.46
Preliminary report: genetic variation in the human stromelysin promoter is associated with progression of coronary atherosclerosis. Br Heart J (1995) 1.41
The ACE gene and muscle performance. Nature (2000) 1.40
Two promoter polymorphisms regulating interleukin-6 gene expression are associated with circulating levels of C-reactive protein and markers of bone resorption in postmenopausal women. J Clin Endocrinol Metab (2003) 1.38
Stromelysin-1 and interleukin-6 gene promoter polymorphisms are determinants of asymptomatic carotid artery atherosclerosis. Arterioscler Thromb Vasc Biol (2000) 1.36
Mutation detection rate and spectrum in familial hypercholesterolaemia patients in the UK pilot cascade project. Clin Genet (2010) 1.29
INSIG2 gene polymorphism is not associated with obesity in Caucasian, Afro-Caribbean and Indian subjects. Int J Obes (Lond) (2007) 1.28
Heritability of C-reactive protein and association with apolipoprotein E genotypes in Japanese Americans. Ann Hum Genet (2004) 1.27
Family history is a coronary heart disease risk factor in the Second Northwick Park Heart Study. Ann Hum Genet (2003) 1.27
Candidate gene association studies in abdominal aortic aneurysm disease: a review and meta-analysis. Eur J Vasc Endovasc Surg (2007) 1.25
Lack of association between the insertion/deletion polymorphism of the angiotensin-converting enzyme gene and idiopathic dilated cardiomyopathy. J Am Coll Cardiol (1995) 1.24
Common variation in the lipoprotein lipase gene: effects on plasma lipids and risk of atherosclerosis. Atherosclerosis (1997) 1.22
A common restriction fragment length polymorphism of the human apolipoprotein E gene and its relationship to type III hyperlipidaemia. Hum Genet (1987) 1.21
Description of a dinucleotide repeat polymorphism in the human elastin gene and its use to confirm assignment of the gene to chromosome 7. Ann Hum Genet (1993) 1.20
Lipoprotein (a) as a predictor of myocardial infarction in middle-aged men. Am J Med (2001) 1.19
beta-Adrenergic regulation of IL-6 release from adipose tissue: in vivo and in vitro studies. J Clin Endocrinol Metab (2001) 1.19
The isolation of a genomic clone containing the apolipoprotein CII gene and the detection of linkage disequilibrium between two common DNA polymorphisms around the gene. Hum Genet (1984) 1.18
Spectrum of LDL receptor gene mutations in heterozygous familial hypercholesterolemia. Hum Mutat (1997) 1.18
Evidence for a third genetic locus causing familial hypercholesterolemia. A non-LDLR, non-APOB kindred. J Lipid Res (1999) 1.17
Established and emerging coronary risk factors in patients with heterozygous familial hypercholesterolaemia. Heart (2004) 1.17
Low-grade inflammation may play a role in the etiology of the metabolic syndrome in patients with coronary heart disease: the HIFMECH study. Metabolism (2004) 1.17
EPCR Ser219Gly: elevated sEPCR, prothrombin F1+2, risk for coronary heart disease, and increased sEPCR shedding in vitro. Atherosclerosis (2005) 1.17
The significant increase in cardiovascular disease risk in APOEepsilon4 carriers is evident only in men who smoke: potential relationship between reduced antioxidant status and ApoE4. Ann Hum Genet (2005) 1.15
Probabilistic cost-effectiveness analysis of cascade screening for familial hypercholesterolaemia using alternative diagnostic and identification strategies. Heart (2011) 1.15
Polymorphisms at the apoB, apoA-I, and cholesteryl ester transfer protein gene loci in patients with gallbladder disease. J Lipid Res (1995) 1.14
The apolipoprotein A-V genotype and plasma apolipoprotein A-V and triglyceride levels: prospective risk of type 2 diabetes. Results from the Northwick Park Heart Study II. Diabetologia (2006) 1.14
The endothelial nitric oxide synthase (Glu298Asp and -786T>C) gene polymorphisms are associated with coronary in-stent restenosis. Eur Heart J (2002) 1.14
Adiponectin and its gene variants as risk factors for insulin resistance, the metabolic syndrome and cardiovascular disease. Atherosclerosis (2006) 1.13
Truncated variants of apolipoprotein B cause hypobetalipoproteinaemia. Nucleic Acids Res (1988) 1.13
Cascade screening for familial hypercholesterolaemia: implications of a pilot study for national screening programmes. J Med Screen (2006) 1.13
Familial defective apolipoprotein B-100: detection in the United Kingdom and Scandinavia, and clinical characteristics of ten cases. Atherosclerosis (1990) 1.13
A molecular genetic service for diagnosing individuals with familial hypercholesterolaemia (FH) in the United Kingdom. Eur J Hum Genet (2001) 1.12
Contribution of apolipoprotein C-III gene variants to determination of triglyceride levels and interaction with smoking in middle-aged men. Arterioscler Thromb Vasc Biol (2000) 1.12
Interleukin-18 genetics and inflammatory disease susceptibility. Genes Immun (2007) 1.11
Census of clinics providing specialist lipid services in the United Kingdom. J Public Health (Oxf) (2004) 1.11
The molecular genetics of cardiovascular disease: clinical implications. J Intern Med (2003) 1.11
Characterization of the lipid-binding properties and lipoprotein lipase inhibition of a novel apolipoprotein C-III variant Ala23Thr. J Lipid Res (2000) 1.10
Plasma thrombin-activatable fibrinolysis inhibitor antigen concentration and genotype in relation to myocardial infarction in the north and south of Europe. Arterioscler Thromb Vasc Biol (2002) 1.08
Identification of a deletion in the low density lipoprotein (LDL) receptor gene in a patient with familial hypercholesterolaemia. Hum Genet (1985) 1.08
The gene for apolipoprotein C-II is closely linked to the gene for apolipo-protein E on chromosome 19. Clin Genet (1984) 1.07
Low-density lipoprotein receptor gene (LDLR) world-wide website in familial hypercholesterolaemia: update, new features and mutation analysis. Atherosclerosis (2001) 1.06
Chromatin structure of the 5S ribonucleic acid genes of Xenopus laevis. Biochemistry (1979) 1.05
The ACE I/D polymorphism and human physical performance. Trends Endocrinol Metab (2000) 1.05
Gene-environment and gene-gene interaction in the determination of plasma homocysteine levels in healthy middle-aged men. Thromb Haemost (2001) 1.03
Polymorphisms in the apolipoprotein (apo) AI-CIII-AIV gene cluster: detection of genetic variation determining plasma apo AI, apo CIII and apo AIV concentrations. Hum Genet (1992) 1.03
Associations between lipoprotein lipase gene polymorphisms and plasma correlations of lipids, lipoproteins and lipase activities in young myocardial infarction survivors and age-matched healthy individuals from Sweden. Atherosclerosis (1992) 1.03
Association between the Ala379Val variant of the lipoprotein associated phospholipase A2 and risk of myocardial infarction in the north and south of Europe. Atherosclerosis (2003) 1.03
High-throughput method for determination of apolipoprotein E genotypes with use of restriction digestion analysis by microplate array diagonal gel electrophoresis. Clin Chem (1995) 1.02
The interleukin-6 gene -174G>C and -572G>C promoter polymorphisms are related to cerebral aneurysms. J Neurol Neurosurg Psychiatry (2006) 1.02
Effects of six APOA5 variants, identified in patients with severe hypertriglyceridemia, on in vitro lipoprotein lipase activity and receptor binding. Arterioscler Thromb Vasc Biol (2008) 1.02
Association of plasminogen activator inhibitor (PAI)-1 (SERPINE1) SNPs with myocardial infarction, plasma PAI-1, and metabolic parameters: the HIFMECH study. Arterioscler Thromb Vasc Biol (2007) 1.02
Effect on plasma lipid levels of different classes of mutations in the low-density lipoprotein receptor gene in patients with familial hypercholesterolemia. Arterioscler Thromb (1994) 1.01
A DNA polymorphism adjacent to the human apolipoprotein CII gene. Mol Biol Med (1983) 1.01
CYP2C9*3 allelic variant and bleeding complications. Lancet (1999) 1.01
Apolipoprotein B gene polymorphisms are associated with lipid levels in men of South Asian descent. Atherosclerosis (1991) 1.01
Linkage disequilibrium at the cystathionine beta synthase (CBS) locus and the association between genetic variation at the CBS locus and plasma levels of homocysteine. The Ears II Group. European Atherosclerosis Research Study. Ann Hum Genet (1998) 1.00
The plasminogen activator inhibitor-1 -675 4G/5G genotype influences the risk of myocardial infarction associated with elevated plasma proinsulin and insulin concentrations in men from Europe: the HIFMECH study. J Thromb Haemost (2003) 1.00
Ethnic differences in fibrinogen levels: the role of environmental factors and the beta-fibrinogen gene. Am J Epidemiol (2001) 0.99
Universal primer quantitative fluorescent multiplex (UPQFM) PCR: a method to detect major and minor rearrangements of the low density lipoprotein receptor gene. J Med Genet (2000) 0.98
The isolation and characterization of cDNA clones for human apolipoprotein CII. J Biol Chem (1984) 0.98
A common mutation (G-455--> A) in the beta-fibrinogen promoter is an independent predictor of plasma fibrinogen, but not of ischemic heart disease. A study of 9,127 individuals based on the Copenhagen City Heart Study. J Clin Invest (1997) 0.98
Genetic variation on chromosome 16 is associated with abdominal aortic aneurysm. Clin Sci (Lond) (1990) 0.97
Variable effects of the APOC3-482C > T variant on insulin, glucose and triglyceride concentrations in different ethnic groups. Diabetologia (2001) 0.97
A functional polymorphic variant in the interleukin-6 gene promoter associated with low bone resorption in postmenopausal women. Arthritis Rheum (2001) 0.96
Cost-effectiveness analysis of the use of a high-intensity statin compared to a low-intensity statin in the management of patients with familial hypercholesterolaemia. Curr Med Res Opin (2010) 0.96
ApoCIII gene variants modulate postprandial response to both glucose and fat tolerance tests. Circulation (1999) 0.96
Age-related effects of genetic variation on lipid levels: The Columbia University BioMarkers Study. Pediatrics (2001) 0.96
Dietary oleic and palmitic acids and postprandial factor VII in middle-aged men heterozygous and homozygous for factor VII R353Q polymorphism. Am J Clin Nutr (1999) 0.96